Industry Briefs: October 22, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: October 22, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI has extended its API supply agreement with Shire. Read More

Aptuit has announced the offering of antibacterial studies from a single site, the Aptuit Center for Drug Discovery & Development in Verona, Italy.

The National Institute of Allergy and Infectious Diseases has awarded Pfenex a contract to develop an alternative delivery method for its recombinant protective antigen (rPA)-based anthrax vaccine. Read More

Pluristem Therapeutics has achieved a milestone towards the completion of its new GMP manufacturing facility for commercial production of the company’s Placental eXpanded cells. Read More

The United States Pharmacopeial Convention (USP) has selected the Thermo Scientific TruScan RM and microPHAZIR RX instruments to support its recent initiative to provide USP-approved spectral libraries to pharmaceutical manufacturers. Read More

People News

AMRI has appointed Steven R. Hagen as senior vice-president of pharmaceutical development and manufacturing. Read More

Cobra Biologics has appointed John Birch, former chief scientific officer for Lonza Biopharmaceuticals, as a nonexecutive director. Read More

ISPE has announced its 2012–2013 board of directors election results, including Charlotte Enghave Fruergaard as chair and Damian Greene as vice-chair. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here